









Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on April 2024

Classification of products:

Status	Description
 GREEN	Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
 AMB 1	Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline.
 AMB 2	Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing.
 AMB SCP	AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only).
 RED	Red-Hospital initiation and continuation only
 GREY	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)
 PURPLE	To be supplied from the appropriate commissioned provider.
 NR	Not routinely commissioned

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
Nil this month				
2) New Requests				
Uromune			RED	Feedback from anti-microbial group
Fenfluramine	RED			TA808 - The formulary will reflect the TAG – NHS England is the responsible commissioner.
Foslevodopa-Foscarbidopa	RED			TA934 - The formulary will reflect the TAG – NHS England is the responsible commissioner.
Belimumab	RED			TA572 - The formulary will reflect the TAG – NHS England is the responsible commissioner.

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
3) New formulations & extensions to use				
Levomepromazine Liquid	AMB 1			Restriction for when levomepromazine tablet unavailable/patient unable to take tablets
4) Products considered by NICE				
TA949: Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA950: Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA951: Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA952: Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
5) Appeals against earlier decisions by the APC				
Nil this month				
6) Miscellaneous formulary decisions by the APC				
Nil this month				

The following guidelines were presented to and approved at the April 2024 meeting of the APC:

- Quantities of medicines to be supplied by secondary care
- Glycopyrronium amber guidelines

The following Drug information leaflets were presented to and approved at the April 2024 meeting of the APC:

- Nil this month

The following shared care guidelines were presented to and approved at the April 2024 meeting of the APC:

- Nil this month

Other documents presented to and approved at the April 2024 meeting of the APC:

- Nil this month

Pathways approved:

- NLAG biologics in rheumatoid arthritis